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ABSTRACT Topical microbicides are an emerging HIV/AIDS prevention modality. Microbicide biofunctionality requires
creation of a chemical-physical barrier against HIV transmission. Barrier effectiveness derives from properties of the active
compound and its delivery system, but little is known about how these properties translate into microbicide functionality. We
developed a mathematical model simulating biologically relevant transport and HIV-neutralization processes occurring when
semen-borne virus interacts with a microbicide delivery vehicle coating epithelium. The model enables analysis of how vehicle-
related variables, and anti-HIV compound characteristics, affect microbicide performance. Results suggest HIV neutralization is
achievable with postcoital coating thicknesses ;100 mm. Increased microbicide concentration and potency hasten viral neu-
tralization and diminish penetration of infectious virus through the coating layer. Durable vehicle structures that restrict viral
diffusion could provide signiﬁcant protection. Our ﬁndings demonstrate the need to pair potent active ingredients with well-
engineered formulation vehicles, and highlight the importance of the dosage form in microbicide effectiveness. Microbicide
formulations can function not only as drug delivery vehicles, but also as physical barriers to viral penetration. Total viral neu-
tralization with 100-mm-thin coating layers supports future microbicide use against HIV transmission. This model can be used as
a tool to analyze diverse factors that govern microbicide functionality.
INTRODUCTION
The HIV pandemic continues to overwhelm current preven-
tative measures at a rate of 12,000 new infections a day (1).
Women account for a disproportionate number of these new
infections. Most of the infected young people are aged 15–24
worldwide, and 59% of all infected adults in sub-Saharan
Africa are female. In several African countries, prevalence
rates for young women (ages 15–24) are over three times
higher than their male counterparts (1). Increased biological
vulnerability, combined with cultural and socioeconomic
inequities, results in greater HIV susceptibility and, conse-
quently, infections in women (2–4). New HIV prevention
methods will beneﬁt women by augmenting their abilities to
manage their sexual health, thus protecting themselves and
their communities.
Microbicide development is a response to this demonstrated
need for new, female-controlled, methods for HIV prophy-
laxis (2–7). Topical vaginal microbicide dosage forms—
which may take forms such as gels, creams, ﬁlms, sponges,
or rings—are intended to prevent transmission of HIV and/or
other sexually introduced pathogens, providing women with
safe, affordable, and cosmetically acceptable protection. Micro-
bicides may function by disabling pathogens, hindering
pathogen transport, protecting tissue from injury, inhibiting
early infectious processes, or combinations of the above.
An effective microbicide may combine a potent active in-
gredient that neutralizes target pathogens with a well-engineered
formulation vehicle that delivers the active ingredient while
providing a barrier and lubrication layer. To date, the
majority of microbicide research has focused on identifying,
testing, and manufacturing the active compounds. However,
there remain many unanswered questions about the role and
importance of the delivery vehicle in microbicide efﬁcacy.
Several laboratories, including ours, have designed in vitro
and in vivo experiments, and mathematical epithelial coating
theories, to begin to understand the determinants of micro-
bicide formulation distribution within the complex physio-
logical vaginal environment (8–12). However, there has been
very little investigation to date into the collective, quantitative
impact that coating layer properties (e.g., extent, durability,
thickness, structure) have on microbicide prophylactic efﬁ-
cacy.
Our goal here was to create a model that simulates relevant
transport and HIV neutralization processes inherent in micro-
bicide function, and to use that model to understand and
predict the effects that several critical microbicide vehicle
properties have on ultimate HIV prophylaxis in vivo. We
develop a system of transport equations for both virus, origi-
nating in the semen, and a mobile anti-HIV agent, originat-
ing in an epithelial coating layer. These equations track
the simultaneous migration of virus and microbicide while
accounting for their interaction. We develop an expression
for viral neutralization in terms of speciﬁc microbicide
binding kinetics. The analysis in this initial study focuses on
neutralization of HIV by a gp120 fusion inhibitor. Because
the processes that neutralize HIV fusion must occur before
epithelial contact—i.e., within the formulation/semen system—
fusion inhibiting compounds were logical choices for this
analysis. The protein Cyanovirin-N (CV-N) was chosen as
an example fusion inhibitor due to the large amount of
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published research characterizing its activity and its current
status as a promising microbicide (13–18). However, the
conceptual mathematical framework used here is broadly
applicable to a number of potential microbicide prophylactic
mechanisms. Microbicide effectiveness—a function of factors
speciﬁc to given formulated vehicles and active ingredients—
can then be determined by examining the rate at which in-
fectious virus reaches epithelial tissue.
MATERIALS AND METHODS
The interacting transport processes of HIV virions and microbicide
molecules can be modeled by a two-compartment, two-component, one-
dimensional, unsteady diffusion system with bimolecular viral neutralization
terms (Fig. 1). We assume transmission from HIV-infected semen, existence
of a uniform formulation coating layer over epithelium, and we focus on
diffusive, postcoital transport of cell-free HIV. The assumption of one-
dimensional diffusion is justiﬁed because the thicknesses of epithelial
coating layers are typically very small compared to the lateral extents of
those layers (8). Although cell-associated virus may play a role in HIV
transmission, we have omitted its transport here because of its signiﬁcantly
lower rate of diffusion through a formulation layer. We track more the
mobile cell-free virus because it will reach the epithelium sooner. This
provides a conservative (i.e., lower bound) estimate of the time virus needs
to cross the formulation layer.
Governing equations of transport
These equations characterize transport and reversible interactions of virus
and generic mobile active ingredient within the semen-formulation system.
They provide a foundation that we subsequently expand to incorporate
neutralization kinetics for CV-N. Variable deﬁnitions and example values
are given in Table 1.
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Boundary and initial conditions
We assume that no virus or microbicide leave or enter the system from the
upper surface of the semen layer (Eq. 3). Physiologically, this boundary may
be open to air; or a symmetric, inverted semen/formulation layer could be
vertically adjacent to this system (i.e., we would be considering the bottom
half of a symmetric system).
@CVðeL; tÞ
@x
¼ 0 @CMðeL; tÞ
@x
¼ 0: (3)
We apply standard concentration and ﬂux boundary conditions at the
semen-formulation interface (Eqs. 4 and 5).
CVð01 ; tÞ ¼ FVCVð0; tÞ CMð01 ; tÞ ¼ FMCMð0; tÞ (4)
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Beneath the formulation layer, mucosal epithelium presents a signiﬁcant
barrier to transport (5). We calculate the rate at which microbicide is trans-
ported into the epithelium using permeability values taken from relevant
literature (19–21). Mechanisms by which HIV crosses the mucosal barrier
are not well understood; however, we assume that the rate of transepithelial
viral transport is much slower than the rate of viral transport within the for-
mulation. This viral ‘‘bottleneck’’ (5) allows us to neglect viral permeability
in our boundary conditions (Eq. 6). Infection can be understood as a con-
sequence of the local concentration at the interface.
@CVðL; tÞ
@x
¼ 0 @CMðL; tÞ
@x
¼ PepiCM: (6)
Initially, all infectious virus is within the semen, and all microbicide is in
the formulation layer (Eq. 7).
CVðx; 0Þ ¼ CVo
CMðx; 0Þ ¼ 0

for  eL# x, 0
CVðx; 0Þ ¼ 0
CMðx; 0Þ ¼ CMo

for 0# x#L: (7)
Viral neutralization kinetics
The viral neutralization term is of the form:
kfCMCV1 krCN: (8)
This expression represents reversible binding and neutralization of one
microbicide molecule to a virion. Neutralization kinetics are mechanism
dependent, and will vary for given anti-HIV agents. We use the fusion inhibitor,
Cyanovirin-N (CV-N), as an example microbicide to demonstrate our model.
CV-N is an 11-kD protein that is derived from blue-green algae and neutralizes
HIV by binding with high afﬁnity to gp120, a glycoprotein projection on the
virion’s surface. This prevents gp120 from interacting with cellular CD4 and
initiating fusion, thereby preventing infection (14–18). Studies of binding
stoichiometry have suggested that up to 5 CV-Nmolecules may bind to a single
soluble, nontrimeric, nonvirion associated gp120 (18). However, trimeric,
virion-associated gp120 may exhibit different stoichiometry. It has been shownFIGURE 1 Geometry of model system.
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that approximately two CV-N molecules are needed to inhibit binding to cell-
associated CD4 (14,17). Therefore, while a 5:1 CVN-gp120 ratio may be
possible, 2:1 is sufﬁcient to inhibit fusion.
Mature HIV displays ;10 gp120 trimers on its surface (22–26); all
trimers must be blocked for neutralization (22,24,27). The presence of 10
glycoprotein trimers, each with three gp120s requiring two CV-N for
inactivation, results in a maximum of 60 separate CV-N binding events per
virion. Recent research has suggested that blocking two out of three gp120
per trimer is sufﬁcient to inactivate a trimer (28). Therefore, 50 binding
events must occur for HIV neutralization (i.e., each gp120 has one CV-N
and 20 gp120s have at least two CV-N.)
Weassume that binding is diffusion limited, andweapply collision theory to
develop approximate association constants. This assumption is valid due to
very low KD (2–45 nM) values of CV-N and other current microbicidal
compounds (18). Therefore, the molar rate of inactivation, assuming instan-
taneous binding upon collision for a virion with one glycoprotein stalk, is the
product of CV-N ﬂux to the virion (CCVNðDCVN1DHIVÞ= RHIV) and the
accessible hemispherical surface area of the active site (2pR2trimer).Weﬁnd that:
molar rate of binding for a single trimer
¼ 2pNAðDCVN1DHIVÞR
2
trimer
1000RHIV
 
CCVNCV: (9)
Avogadro’s number and division by 1000 were needed to convert from
cgs units to molar quantities.
Calculations using the derived association constant (kf)—the bracketed
term in Eq. 9—compare very well with experimental values of CV-N
binding to gp120 (14,18). Previously, BIACORE assays produced values of
kf in the 10
6 M1s1 range, and kr values around 10
3 s1 (18). These studies
may underestimate the true association constant, due to mass-transport limi-
tations arising from slow diffusion of the large protein and from fast binding
(29). Other titration studies have estimated the association constant to be
around 2.43 107M1s1 (14). Note that these measurements were performed
with soluble gp120, and were not tests for HIV neutralization.
Because 50 separate binding events must occur for actual HIV neu-
tralization, the neutralization term (Eq. 8) must be expanded and adapted to
include multiple binding events. Simultaneous or sequential binding models
are not appropriate for this case. Therefore, we adapted a model employed
by Perelson to describe multivalent receptors as a set of independent
monovalent receptors (30). If we assume that the two separate binding sites
on gp120 do not interact, due to the large size difference between CV-N and
gp120 (11 vs. 120 kD), we have a set of 60 monovalent receptors (15,25).
We can then use statistical kinetic theory to describe how small molecules
bind to multiple identical binding sites (31). This results in a correction to the
equilibrium constant to account for the number of free receptors before
binding and the number of occupied receptors after binding. The dependence
of previously bound receptors on the binding reaction is as follows (31):
ðn i1 1ÞkfCVi1CM ðiÞkrCVi ; (10)
where n is the total number of receptors and i is the number of bound
receptors resulting from the reaction (i.e., the reaction is binding the ith site).
Each of the 60 receptors can exist in two states: bound and unbound. Our
model accounts for 61 interconverting virus populations (i.e., HIV with 0 CV-N
bound through 60 bound) in two separate compartments (semen and vehicle).
Combined with tracking virus and microbicide in both compartments, this
expands the model from 4 to 124 simultaneous equations. The model tracks
virus and microbicide in space and time, identifying virus in various states of
neutralization. A schematic of viral neutralization kinetics is shown in Fig. 2.
Because the model distinguishes virions by the number of CV-N bound, the
number of binding events per trimer needed to fully neutralize a virion (initially 5
CV-Nper trimer) can bemodiﬁed by simply changing the threshold atwhich that
virion is counted as neutralized (i.e., all virus with less than 50 CV-N bound).
Complete nondimensionalized equations
Model transport equations (Eqs. 1 and 2) were nondimensionalized using the
following transformations.
x˜ ¼ x
L
C˜Vi ¼
CVi
CV0
t˜ ¼ tkfCM0 ; (11)
where CVi is the concentration of virus with i CV-N bound, and CV0 is the
initial concentration of all virus.
Because microbicide concentration is many orders of magnitude larger than
viral concentration (Table 1), we assume that any loss of microbicide due to
viral binding is negligible. Not all 124 equations are shown, for compactness.
TABLE 1 Relevant parameters and reference conditions
Variable Deﬁnition Reference conditions
CV0 Initial virus concentration in semen 1.66 3 10
15 M
CVi Virus with i CV-N bound –
CM0 Initial microbicide concentration in coating layer 1000.0 3 10
9 M
CM Microbicide concentration in coating layer –
CN Neutralized virus concentration –
DVsemen Diffusion coefﬁcient of virus in semen 6.49 3 10
9 cm2 s1
DVgel Diffusion coefﬁcient of virus in coating layer 6.49 3 10
11 cm2 s1
DMsemen Diffusion coefﬁcient of microbicide in semen 1.72 3 10
7 cm2 s1
DMgel Diffusion coefﬁcient of microbicide in coating layer 1.72 3 10
8 cm2 s1
DCVN Diffusion coefﬁcient of CV-N in a medium –
DHIV Diffusion coefﬁcient of HIV in a medium –
kfsemen Forward kinetic constant in semen 4.72 3 10
6 M1 s1
krsemen Reverse kinetic constant in semen 4.7 3 10
3 s1
kfgel Forward kinetic constant in coating layer 4.57 3 10
5 M1 s1
krgel Reverse kinetic constant in coating layer 4.57 3 10
4 s1
L Formulation thickness 100 mm
NA Avogadro’s number 6.02 3 10
23
FV,FM Semen/formulation partition coefﬁcient 1
Pepi Epithelial permeability to microbicide 10
6 cm s1
RHIV Radius of HIV 70 nm
Rtrimer Radius of gp120 trimer 7 nm
– Dimensions of CV-N 55 3 25 A˚
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Dimensionless equations within semen layer (2e# x , 0)
@C˜V0ðx; tÞ
@ t˜
¼ DVsemen
kfgelCM0L
2
@
2C˜V0ðx; tÞ
@x˜
2
 60kfsemen
kfgel
C˜V0ðx; tÞC˜Mðx; tÞ1
krsemen
kfgelCM0
C˜V1ðx; tÞ
@C˜V1ðx; tÞ
@ t˜
¼ DVsemen
kfgelCM0L
2
@
2
C˜V1ðx; tÞ
@x˜2
1 60
kfsemen
kfgel
C˜V0ðx; tÞC˜Mðx; tÞ 
krsemen
kfgelCM0
C˜V1ðx; tÞ
 59kfsemen
kfgel
C˜V1ðx; tÞC˜Mðx; tÞ1 2
krsemen
kfgelCM0
C˜V2ðx; tÞ
@C˜V2ðx; tÞ
@ t˜
¼ DVsemen
kfgelCM0L
2
@
2
C˜V2ðx; tÞ
@x˜
2
1 59
kfsemen
kfgel
C˜V1ðx; tÞC˜Mðx; tÞ  2
krsemen
kfgelCM0
C˜V2ðx; tÞ
 58kfsemen
kfgel
C˜V2ðx; tÞC˜Mðx; tÞ1 3
krsemen
kfgelCM0
C˜V3ðx; tÞ
:
:
@C˜V59ðx; tÞ
@ t˜
¼ DVsemen
kfgelCM0L
2
@
2
C˜V59ðx; tÞ
@x
2 1 2
kfsemen
kfgel
C˜V58ðx; tÞ
3 C˜Mðx; tÞ  59 krsemen
kfgelCM0
C˜V59ðx; tÞ
 kfsemen
kfgel
C˜V59ðx; tÞC˜Mðx; tÞ1 60
krsemen
kfgelCM0
C˜V60ðx; tÞ
@C˜V60ðx; tÞ
@ t˜
¼ DVsemen
kfgelCM0L
2
@
2
C˜V60ðx; tÞ
@x˜2
1
kfsemen
kfgel
C˜V59ðx; tÞC˜Mðx; tÞ
 60 krsemen
kfgelCM0
C˜V60ðx; tÞ
@C˜Mðx; tÞ
@ t˜
¼ DMsemen
kfgelCM0L
2
@
2
C˜Mðx; tÞ
@x˜
2 : (12)
Dimensionless equations within formulation layer (0 , x #1)
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Dimensionless boundary conditions (adapted from Eqs. 3–6)
No transport from semen layer:
@C˜Viðe; t˜Þ
@x˜
¼ 0 @C˜Mðe; t˜Þ
@x˜
¼ 0: (14)
Semen-vehicle interface:
C˜Við01 ; t˜Þ ¼ FVC˜Við0; t˜Þ C˜Mð01 ; t˜Þ ¼ FMC˜Mð0; t˜Þ
(15)
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FIGURE 2 Schematic of viral neutralization kinetics.
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Epithelium impermeable to virus, slightly permeable to microbicide:
@C˜Við1; t˜Þ
@x˜
¼ 0 @C˜Mð1; t˜Þ
@x˜
¼ PepiL
DMg
C˜M: (17)
Dimensionless initial conditions (adapted from Eq. 7)
All virus unbound and in semen; all microbicide in vehicle:
C˜V0ðx˜; 0Þ ¼ 1
C˜Vi. 0ðx˜; 0Þ ¼ 0
C˜Mðx˜; 0Þ ¼ 0
9>=
>; for  e# x˜, 0
C˜Viðx˜; 0Þ ¼ 0
C˜Mðx˜; 0Þ ¼ 1
)
for 0# x˜#1: (18)
System parameters (Table 1)
Concentrations of virus and microbicide
Viral load in human semen can reach concentrations of over 106/ml (1.663
10215 M). Here, we have conservatively applied this relatively high viral
concentration for humans, to maximally challenge the microbicide vehicle
(32,33).
Initial microbicide concentrations within a drug delivery vehicle are
likely to be orders of magnitude higher than seminal viral concentrations,
due to the low molar concentration of virus in semen. Because CV-N has
nanomolar potency, actual formulation loading will most likely be in the
micromolar range. Here we consider both a micromolar concentration, as
well as a 100-fold reduction in that concentration, to demonstrate concen-
tration effects on viral neutralization.
Diffusion coefﬁcients of virions and microbicide molecules
We are modeling postcoital transport within the semen-vehicle system as
diffusion dominated. Assuming semen to be a Newtonian ﬂuid with viscosity
5 cP (34), we estimate the diffusion coefﬁcients of virus and anti-HIV
particles in the semen using the Stokes-Einstein equation (26). The diffusion
coefﬁcient of an HIV virion in semen (DVsemen ¼ 6:4931029cm2s21) at 37C
is calculated for a 70-nm radius sphere, whereas the diffusion coefﬁcient of
the microbicide molecule CV-N (DMsemen ¼ 1:7231027cm2s21) is calculated
for a prolate spheroid with major axis 55 A˚ andminor axis 25 A˚ (14,35). Note
that the larger size of the virion results in a diffusion coefﬁcient that is over
25 times smaller than that of the microbicidal molecule (Table 1).
Particle transport (virion, microbicide) through the microbicide vehicle
coating layer may be restricted, in comparison to semen, due to the vehicle’s
molecular microstructure. Diffusion coefﬁcients in the vehicle for both virus
(DVg) and microbicide (DMg) will vary depending upon local vehicle
properties, which may change with time and space. Little is currently known
about restricted diffusion of HIV or CV-N; we consider high and low values
of estimated diffusion coefﬁcients to bracket biologically relevant ranges for
both virus and microbicide. The high values for both particles derive from
assuming no restriction of particle transport by the vehicle versus semen.
The low values restrict diffusion 100-fold for the larger virus and 10-fold for
the smaller CV-N. These values are approximations based on studies of
diffusion of similar particles in hydrogels (36). Diffusion coefﬁcients remain
constant throughout the vehicle in this initial model.
Epithelial permeability
A multilayered stratiﬁed squamous epithelium exists along the vagina and
ectocervix. This tissue transforms to a tight-junction columnar epithelium at
the entrance to the cervical canal. There have been a number of studies on
the permeability of epithelium to various compounds. Human cervical and
vaginal epithelium have been shown to have permeability coefﬁcients
between 0.5 3 1026 and 22 3 1026 cm/s for relatively hydrophilic
substances, ranging in size from tritiated water to 10 kD polydextrans (19–
21,37). Cervical epithelium is slightly more permeable, as expected given its
structure. Other studies on buccal, sublingual, and corneal tissue in pigs and
rabbits have found similar permeability values (38–41). Here we consider
examples in which permeability of epithelium to CV-N is ;1026cm/s. HIV
permeability is assumed to be negligible due to its larger size, resulting in a
no-ﬂux condition on viral transport. Physiologically, this results in the total
amount of virus in the system remaining constant. Because the analysis here
is primarily concerned with whether any infectious virus reaches the
epithelial surface, the consequences of this assumption, namely, a slightly
higher viral concentration at the boundary at very long times and the lack of
quantiﬁcation of viral transport into the epithelial compartment, do not affect
the analysis of the results.
Layer thickness
The thickness (L) of the microbicide vehicle coating layer most likely ranges
from nearly 0 to ;1000 mm, depending on the amount inserted and its
subsequent interactions within the vaginal environment. We used 100 mm as
a reference value for computations and initially assumed equal thicknesses
for both the semen and microbicide coating layer.
Partition coefﬁcient
Because many hydrogel formulations are hydrophilic and have high water
content, the semen/vehicle interface will very quickly become indistinct.
Here we assume the partition coefﬁcient to be unity. This is a conservative
estimate and may overestimate the amount of virus that enters the vehicle
coating layer.
RESULTS
The set of 124 simultaneous transport equations was eval-
uated using the partial differential equation solver, ‘‘pdepe’’,
found in MATLAB (The Mathworks, Natick, MA). Outputs
give concentrations of virus (in various states of neutraliza-
tion) and of microbicide as functions of time and space, and
of system properties, including: viral load in semen, micro-
bicide concentration/potency, binding kinetics, thicknesses
of microbicide vehicle and semen layers, and mobilities of
virus and microbicide in those layers. The model was
initially applied to a set of reference conditions (Table 1)
to provide a baseline for subsequent comparisons. Initially,
semen and vehicle layers are the same thickness, and the
vehicle is assumed to restrict diffusion. Several factors, in-
cluding microbicide concentration, viral and microbicide
mobility, and layer thickness were then altered, and their
effects analyzed and interpreted.
Reference conditions
Fig. 3 A shows infectious virus within the semen layer.
Under the reference conditions, the microbicide diffuses into
and neutralizes virus within semen before any infectious
virus enters the vehicle layer. Fig. 3 B depicts the same
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FIGURE 3 Viral neutralization model outputs. The top (100/ 0 mm) is semen layer, and the bottom (0/ 100 mm) is formulation layer. Color-bar
denotes concentration values relative to initial concentration. (A) Infectious virus concentration; reference conditions. (B) Total (grayscale) and infectious
(color) virus concentration; reference conditions. (C) Microbicide concentration; reference conditions. (D) Infectious virus concentration; microbicide potency
reduced 1003. (E) Infectious virus concentration; microbicide potency reduced 1003 and viral and microbicide transport unhindered. (F) Infectious virus
concentration; microbicide potency reduced 1003, viral and microbicide transport unhindered, and 50 mm formulation thickness. White line in panels E and
F denotes 1 log reduction from seminal viral load.
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conditions, but shows the transport of all virus; although
virus begins to penetrate the layer within a few minutes, it
has already been neutralized by the microbicide.
Distribution of the microbicide compound under the
reference conditions is shown in Fig. 3 C. The microbicide
diffuses into the semen where it neutralizes HIV. Due to the
higher absolute concentration of microbicide as compared to
virus, even a relatively small concentration of microbicide
can have a signiﬁcant effect on virus neutralization. Note
that microbicide is continually being lost to epithelium and
its concentration in the vehicle is markedly decreased within
an hour.
Less potent active ingredient
Modifying parameters in the reference conditions, we
illustrate the sensitivity of HIV neutralization kinematics to
several critical properties of the microbicide delivery vehicle
system. Fig. 3 D illustrates the effect of a less potent active
ingredient, i.e., here we have reduced kr/kf by 1003. The
microbicide is not able to neutralize the virus within the
semen layer, and at longer times infectious virus begins to
inﬁltrate the vehicle layer, although its transport is still
hindered by the vehicle. Note in Eqs. 12 and 13 that an equal
magnitude drop of initial microbicide concentration would
have an identical effect because of the ðkrgel=kfgelCM0Þ term in
the governing equations.
Unrestricted diffusion
In all the previous examples, both viral and microbicide
transport were hindered by the vehicle layer as compared to
semen. Depending on the microstructure of the vehicle, this
might not always be the case. That is, if a vehicle were not
engineered for the vaginal environment, the process of
dilution, and subsequent swelling, may change its micro-
structure and reduce its restrictive effect on particle diffu-
sion. Fig. 3 E shows the same conditions as in Fig. 3 D,
except that there is no restriction of diffusion, and the viral
particles have the same mobility both in semen and the
vehicle. Note that, in the absence of restricted diffusion, a
previously adequate coating layer (with a given concentra-
tion and potency) becomes ineffective. Infectious virus
concentration rises quickly at the epithelial surface.
Unrestricted diffusion plus a thinner
formulation layer
As the microbicide vehicle layer becomes thinner, its effec-
tiveness begins to be compromised. Fig. 3 F shows the same
conditions as Fig. 3 E, but the vehicle thickness is halved to
50 mm. As expected, infectious HIV is able to traverse the
vehicle layer more quickly. A more rapid loss of microbicide
to the epithelium from such a thin layer further exacerbates
the situation. This scenario represents a microbicide layer
that has been rendered ineffective due to dilution and dimin-
ished thickness.
SENSITIVITY ANALYSIS
This analysis is originally based on the assumption that each
virion has ;10 glycoprotein trimers projecting from its
surface. This number of trimers represents an average value
and may vary both within a given population of virus and
between viral stocks. Therefore, we investigated whether
variation in trimer number affected our results. We modiﬁed
the model (by shrinking or expanding the number of equa-
tions) to represent a virus population with a 50% increase or
decrease in the number of trimers (i.e., virus with ﬁve or 15
trimers versus the original 10). We compared results among
the different cases by evaluating both concentration proﬁles
of infectious virus and summary measures that give the times
needed for either total neutralization of virus or for initial
viral-epithelial contact. In all cases studied, the change in the
number of trimers had very minimal effect on the results of
the computations. Compared to the much higher microbicide
concentration, this relatively small increase or decrease in the
number of receptors (trimers) was negligible. Fig. 4 shows a
representative case for the reference conditions.
We also wished to test the assumption that ﬁve binding
events per trimer are needed for viral inactivation. This can
be changed by simply increasing or decreasing the neutral-
ization threshold that deﬁnes virus as infectious or neutral-
ized. Because trimer number does not inﬂuence results, we
tested three different neutralization conditions for the 10
trimer case—3, 4, and 5 CV-N per trimer. This corresponds
to 30, 40, and 50 binding events, respectively. The results are
FIGURE 4 Model insensitivity to trimer number. Time to total viral
neutralization is shown for three different trimer populations. Model
conditions are the reference conditions used in Fig. 3, A–C. Error bars
represent the temporal mesh size used in the MATLAB analysis and show
the uncertainty inherent in the solution. Each case is present for all points;
most points overlap and are indistinguishable from each other.
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shown in Fig. 5. Decreasing binding events increased
microbicide effectiveness. These results are not surprising,
because a decrease in binding events is analogous to in-
creasing microbicide potency or concentration, and the virus
becomes easier to neutralize. The resurgence of infectious
virus at longer times is due to the combined effects of: 1), a
decreased microbicide concentration because of loss due to
ﬁnite epithelial permeability; and 2), the reversible binding
kinetics of CV-N. This highlights a possible advantage for
microbicide compounds that irreversibly inactivate virus.
DISCUSSION
We have developed a dynamic HIV neutralization model that
is applicable to a number of HIV/AIDS prophylaxis contexts,
especially microbicide vehicle functionality. The model
demonstrates interactive effects of several salient active
ingredient and vehicle-speciﬁc parameters. We characterize
microbicide vehicle effectiveness in relation to the local
concentration of infectious virus that reaches the epithelial
surface. Various measures of prophylactic failure can be
deﬁned with respect to this concentration. For example, in this
analysis, we deﬁned a measure of microbicide failure as the
time at which infectious virus was present at the epithelium at a
concentration .10% of the initial viral concentration. To
facilitate the identiﬁcation of this failure point, an iso-
concentration line was drawn in white on the plots denoting a
value of infectious virus concentration one log lower than the
seminal viral load (see Fig. 3, E and F). This analysis also
highlights the importance of the dosage form in microbicide
effectiveness, especially its ability to restrict diffusion and
resist erosion (Fig. 3,D–F). Decreased viral mobilities increase
viral residence times within the delivery system, allowing total
neutralization by moderately potent active compounds long
before epithelial contact. Degradation of the coating layer
before HIV neutralization severely compromises its ability to
provide protection. Outputs from this model suggest that the
thickness of an effective microbicide vehicle coating layer
could realistically be on the order of 100 mm.
Different concentration proﬁles of virus, illustrated in Fig.
3, are consistent with distinctions in values of the diffusion
coefﬁcients (virus and active ingredient) between the semen
and microbicide layers, in relation to potency of the micro-
bicide. This is especially apparent in Fig. 3, A and B, which
illustrate the vehicle’s restrictive effect on viral mobility,
coupled to rapid escape of microbicide into semen. This
produces steep concentration gradients of viable virus near
the semen-vehicle layer interface. In this model, coating
thickness depicts the postcoital state of a vehicle that has
been within the vaginal environment and exposed to ambient
ﬂuids, possibly for a number of hours. We recognize that the
true semen-microbicide interface will not remain discrete
over time: hydration of the vehicle layer will cause a time-
dependent increase in the diffusion coefﬁcient of the virus.
This phenomenon is easily incorporated into the model
by introducing spatial and temporal variability in the viral
diffusion coefﬁcient. It is also possible to include augmented
mobilities of the virus and microbicide due to intravaginal
forces (e.g., epithelial squeezing and coital shearing) that
induce formulation ﬂow. Simpliﬁcations of this initial model
notwithstanding, the results here, which emphasize upper and
lower bounds of viral permeability within microbicide delivery
vehicle layers, are a mechanistically derived and useful guide
for interpreting the efﬁcacy of viral neutralization.
The prospect that a 100-mm-thick microbicide coating
layer can be prophylactic against HIV transmission moti-
vates development of dosage forms that optimize vaginal
distribution and drug delivery around the creation and
persistence of such thin layers. For perspective, applied
volumes of current prototype vaginal microbicide gels range
from ;2–4 ml. The surface area of the human vagina is
likely to be #100 cm2 (42). Thus, an average coating thick-
ness would be $200 mm. Many factors determine the actual
spatial distribution of coating, which is not likely to be
uniformly thick or homogeneous in integrity (8). Nonethe-
less, the results here provide credibility to the notion that
microbicide coating can function to block transport of in-
fectious virus to vulnerable vaginal epithelium. They also
FIGURE 5 Effect of changing neutralization threshold. Figures show same conditions (no viral restriction, decreased microbicide concentration) as in
Fig. 3 E, except with different neutralization conditions.
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suggest that biologically incisive imaging of coating layers
in vivo should employ modalities that can resolve coating
thicknesses of the order of tens of microns (8). We note that
there is also interest in microbicide application to the rectum,
which presents a much larger vulnerable tissue surface area
than the vagina. Here, the local prophylactic capability of
100 mm coating would remain possible; but the feasibility of
achieving such coating over the much larger vulnerable
surface area is uncertain.
Our virus neutralization model provides a framework for
deﬁning, measuring, and interpreting a set of critical
phenomena that collectively govern microbicide product
functionality. These include: binding kinetics between newly
developed entry inhibitors and trimeric, virion associated
gp120; compound-speciﬁc data on the kinetics, stoichiom-
etry, and irreversibility of HIV neutralization; epithelial
permeability to anti-HIV compounds; and diffusion coefﬁ-
cients of HIV in test vehicles (whole and during hydration by
ambient vaginal ﬂuids). The model enables rational, quan-
titative analysis of tradeoffs in effects of these determinants
of microbicide prophylaxis. The geometry of the model is
biologically relevant to in vivo distributions of HIV and
microbicide, and serves to emphasize the need for experi-
mental analyses of microbicides that embody similar conﬁg-
urations. That is, in vitro bioassays of microbicide potency
should include conﬁgurations that resemble the basic multi-
layer structure that originates in vivo and that is embodied in
our model: semen 1 microbicide vehicle 1 epithelium.
Indeed, a powerful component in microbicide development
would be linkage of results of such experiments with pre-
dictions of models such as ours. Additionally, this analysis
has demonstrated the need for quantitative measurements of
particle mobility within potential drug delivery vehicles.
These experiments are currently ongoing in our lab and will
eventually be incorporated into the analysis and design of
future dosage forms.
Understanding factors that enhance or detract from particle
transport would also beneﬁt the design of future dosage for
placebos for microbicide clinical trials. Such placebos should
have the same distribution and retention behavior as the test
microbicide products, and should also have minimal impact
on HIV transmission. Achievement of the former may not be
trivial. (12,43) Moreover, the transport model here has rein-
forced this need for valid placebos in clinical trials (44,45),
because the results clearly show any diffusive restriction by a
placebo coating layer would substantially increase viral
residence time within the vagina, thereby exposing it to the
body’s natural defenses (low pH, hydrogen peroxide, innate
antiviral proteins, etc.) and possibly provide a protective
effect. (5,45) Any anti-HIV efﬁcacy by placebo would have
serious consequences in a randomized, controlled, clinical
trial, because it would reduce the difference between the
prophylactic effects of the test product and its control.
In general, the effects of factors such as microbicide
potency, seminal viral load, layer thickness, mobility, etc.
have nonlinear multivariate impacts on the kinematics of
viral neutralization. Empirical, experimental delineation of
such impacts would be a daunting task, but models of the
type presented here provide a rational guide to such un-
derstanding.
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